Provence Technologies

The deal opens up new development opportunities for the Provence Technologies Group in the area of biologically active pharmaceuticals. Synprosis has a ten-year history of producing active principles in the field of vaccines under development (for malaria, cancer, and allergies, etc.), as well as in other therapeutic fields (for neurogenerative diseases and the treatment of pain). The company was first recognised for its expertise in creating synthetic vaccines for HIV and malaria. The technology developed by Synprosis offers significantly increased peptide production yields with a cost reduction of 30 to 40 per cent.

The Group’s new entity has adopted the name Provepep. Synprosis will be the division specialized in pharmaceutical-standard production, in keeping with good manufacturing practices. Jean-Pierre Salles, who founded Synprosis, will remain in the Provepep executive management team.